Please Click Buy Now to Gain Access to the BUPE2024/Buprenorphine in Medicine Presentations. Thank you!
BUPE2024: Buprenorphine in Medicine is a “virtual conference/resource” for those looking to learn about this exciting molecule and apply it in clinical practice for pain management and addiction medicine. Learn the latest research and practice from experts in the field.
Presentations are available NOW! CMEs and CPEs for BUPE2024 are available now. This is an easy way to earn up to 9.25 CMEs/CPEs! Plus, you will receive a copy of our Journal of Opioid Management special issue on Buprenorphine. It is part of your registration and available for download immediately after you register.
Sign up today! Take advantage of great content, great presenters, our special issue on buprenorphine and get continuing education credit too!
Buprenorphine was conceived by Alan Cowan as a safer opioid analgesic relative to morphine which reduced dysphoria and craving by blocking dysphoria through blocking kappa opioid receptors. It was later found to have a ceiling on respiratory depression demonstrated by the Leiden group of opioid researchers. Its utility as a safer long-acting opioid agonist relative to methadone lead to its adoption into maintenance therapy for those battling substance use disorders. In 2019 the Department of Health and Human Services pain management guidelines recommended the use of buprenorphine, a schedule III opioid, before considering schedule II opioids in managing moderate to severe pain. As the field of pain medicine turns away from traditional strong opioids, alternative options in pain management now include buprenorphine as a frontline opioid analgesic when oral analgesia is necessary. Join us as we explore the expanding role of Buprenorphine in medicine and pain management.
BUPE2024 is a virtual resource. You can browse the great presentation and learn at your pace! Join us!
(BUPE2021 Presentations are available too. You cannot claim CMEs for BUPE2021 videos, but the education is still worth the time. )
